PDCD1 and lipoprotein glomerulopathy: Similarly, with respect to the glomerulus, individual case reports of glomerulopathies as a complication of anti–PD-1 immunotherapy exist (60, 72), though podocyte injury as assessed by foot process effacement was not common in our kidney biopsy cohort.